A practical reference on TB-500: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
=== Engineered === Engineered nanomaterials have been deliberately engineered and manufactured by humans to have certain required properties. Legacy nanomaterials are those that were in commercial production prior to the development of nanotechnology as incremental advancements over other colloidal or particulate materials. They include carbon black and titanium dioxide nanoparticles.
In January 2022, the business announced it would acquire Affera, Inc. In March, Medtronic announced a contract with Vizient, a healthcare performance improvement company, to add Medtronic's Touch Surgery Enterprise platform to Vizient's healthcare offerings. Touch Surgery works with laparoscopic and robotic scopes and is an AI-powered video management and analytics platform for the operating room. In May, Medtronic and DaVita Inc. announced plans to form a new, independent kidney care-focused medical device company. Medtronic's Renal Care Solutions business will be part of the new company. In April 2022, the company announced a collaboration with GE Healthcare to support the needs and care demands at Ambulatory Surgery Centers. In July, Medtronic announced a strategic partnership with CathWorks, a coronary artery disease (CAD) technology developer. A separate agreement gave Medtronic the option to acquire CathWorks in the future. In October 2022, the company announced its intention to pursue a separation of the company's combined Patient Monitoring and Respiratory Interventions businesses, which are part of the company's Medical Surgical Portfolio. In February 2024, the company announced that it had reversed its decision to spin off or sell the Patient Monitoring and Respiratory Interventions businesses, and would instead combine them into a new business unit called Acute Care & Monitoring. They also announced that they would discontinue the ventilator product line, citing its unprofitability.
== Prognosis == The prognosis of primary Raynaud syndrome is often excellent, with no factor to mortality and little morbidity overall. In some very rare cases, gangrene has been known to develop. The prognosis of secondary Raynaud is related to the course of the underlying disease, and how effective blood flow-restoring maneuvers are.
Sources: en.wikipedia.org
Amid the dismantling of apartheid in the early 1990s, various political parties competed over Biko's legacy, with several saying they were the party that Biko would support if he were still alive. AZAPO in particular claimed exclusive ownership over Black Consciousness. In 1994, the ANC issued a campaign poster suggesting that Biko had been a member of their party, which was untrue. Following the end of apartheid when the ANC formed the government, they were accused of appropriating his legacy. In 2002, AZAPO issued a statement declaring that "Biko was not a neutral, apolitical and mythical icon" and that the ANC was "scandalously" using Biko's image to legitimise their "weak" government. Members of the ANC have also criticised AZAPO's attitude to Biko; in 1997, Mandela said that "Biko belongs to us all, not just AZAPO." On the anniversary of Biko's death in 2015, delegations from both the ANC and the Economic Freedom Fighters independently visited his grave. In March 2017, the South African President Jacob Zuma laid a wreath at Biko's grave to mark Human Rights Day.
=== COVID-19 === NUVAXOVID is a recombinant subunit vaccine licensed for the prevention of SARS-CoV-2 infection. Market authorization was issued on 20 December 2021. The vaccine contains the SARS-CoV-2 spike protein produced using the baculovirus expression system, which is eventually adjuvanted with the Matrix M adjuvant.
Not only is the monolith column more economically prudent when considering the value of product processing times, but, at the same time, less media is used, representing a significant reduction in variable costs.
Looking at HM Prison Deerbolt in County Durham and Maudsley Hospital in South London, and divorce and one-parent families had different effects; Iain Duncan Smith talks of being 'victims in society of a social experiment over many decades'; Jonathan Sacks, Baron Sacks talking of a 'national consensus that something was missing in the moral environment'; there was a belief that juvenile crime was linked to single parents and broken homes; Michael Anderson, Professor of Economic History at the University of Edinburgh, claimed that it was all due to current politicians wanting to nostalgically return to a 'golden age' of civility, and he inferred that 'Victorian values' had no importance; a training session for single parents in Maudsley Hospital in Southwark; Michael Wadsworth (sociologist) and the National Survey of Health & Development, which had around 5,000 on the cohort study, and had been set up for establishing the NHS - it showed that divorce increased chances of divorce in children, and of delinquency in children; Martin Richards (psychologist) of the University of Cambridge's Centre for Family Research, and the 1958 National Child Development Study, which looked all of the 17,000 born in one week in early March, and showed similar results to the previous study; the Marriage Research Centre began a study of 65 married couples in 1979; Penny Mansfield CBE of OnePlusOne said that women, after entering the workplace in greater numbers, were now having higher expectations of men's contribution to a marriage; the divorce rate was now 40%, with 33% of divorces occurring in the first five years of marriage; lone parents were now 19% of all British families; for children of divorced parents, 95% would stay with the mother, and within two years, 50% of these children would lose contact totally with their father; Prof John Newson, husband of Elizabeth Newson, and the Child Development Research Unit, founded in 1958 at the University of Nottingham - he said that juvenile delinquency was heavily related to the lower social classes - for the bottom two social classes, one quarter of the children receive a criminal record; David P. Farrington and Donald J. West of the University of Cambridge, conducted a study of 400 London boys born in 1953, known as the Cambridge Study in Delinquent Development; in the study, 37% of all boys acquired a criminal record, but of those with three known determining factors, 75% had a criminal record; 50% of the crime in the study was conducted by only 22 boys, 6% of the total; a study had taken place from 1962 to 1967 in Ypsilanti, Michigan on early years education; similar schemes in the UK were called Head Start, and the main project in the UK was HighScope, with a few schemes at primary schools funded by the Home Office. Directed by Richard Denton, produced by Geoff Deehan, made by Union Pictures 10 October In the Path of a Killer Volcano, with seismologists Dave Harlow, Richard Hoblitt, and John Ewert of the United States Geological Survey; although the biggest volcanic explosion since Krakatoa was about to occur, the seismologists at Philippine Institute of Volcanology, and Seismology (PHIVOLCS) and its director Ray Punongbayan, were mostly totally unaware of anything that abnormal; PHIVOLCS put a seismometer near the volcano, and it recorded over 400 earthquakes in just two days near the summit, so Ray Punongbayan requested urgent assistance from the US Geological Survey; Clark Air Base and U.S. Naval Base Subic Bay were around ten miles away, so seven seismic stations were in place by early May; a helicopter was flown around the site and air samples were taken for a correlation spectrometer to detect any sulphur dioxide, with the ultraviolet; Christopher G. Newhall described how sulphur dioxide detection went from 500 tonnes a day to 5000 tonnes by the end of the month; Mount Katmai in Alaska had been the 20th Century's largest volcanic explosion in early June 1912; a level-4 volcanic event is declared two days before the eruption and 120,000 people are evacuated from a 12-mile radius, but the USAF don't feel the immediate need to move; in only that same week, an eruption had been watched on Mount Unzen in Japan, and its pyroclastic flow, but those scientists who felt apparently safe when watching at close hand were caught out when the flow unexpectedly changed direction and they were trapped and were burned to death; on the morning of 10 June, the USAF base was evacuated 48 hours before the first eruption on 12 June, but the main eruption took place three days later on 15 June, with most of the scientists at the USAF base; the mud flows, known as lahar, caused the most damage by filling rivers so causing many floods; the cloud of debris would circle the globe, and reduced global average temperature by one degree over five years; the 1985 eruption of Nevado del Ruiz in Colombia had led to the Armero tragedy, killing more than 20,000 of the town's 29,000 as the eruption was not forecast. Originally a Nova documentary made in 1992, also produced by Paula S. Apsell, a joint British-American production, produced by Noel Buckner, made by WGBH
Sources: en.wikipedia.org
=== Pharmacokinetics === Absorption: Flupentixol: Readily absorbed in the GI tract. Distribution: Flupentixol: >95% bound to plasma proteins; widely distributed in the body and crosses the blood brain barrier. Metabolism: Flupentixol: Extensively hepatic metabolism. Excretion: Flupentixol: Excreted in urine and faeces in the form of many metabolites.
An exhaustive review article published in March 2009 described the latest information on arteritic and non-arteritic ischemic optic neuropathy, both anterior (A-AION and NA-AION) and posterior (A-PION, NA-PION, and surgical).
Naja annulata (formerly Boulengerina annulata), commonly known as the banded water cobra or the ringed water cobra, is a species of water cobra native to western and central Africa. The species is one of the two species of water cobra in the world, the other one being the Congo water cobra (Naja christyi).
== Biochemistry == 3-Methylhistidine is a metabolic product that is produced in the body via the enzymatic methylation of histidine during peptide bond synthesis and the methylation of actin and myosin.
== Motivations == Scholars discuss current risks from critical systems failures, bias, and AI-enabled surveillance, as well as emerging risks like technological unemployment, digital manipulation, weaponization, AI-enabled cyberattacks and bioterrorism. They also discuss speculative risks from losing control of future artificial general intelligence (AGI) agents, or from AI enabling perpetually stable dictatorships.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.